Competition lawyers have spent two decades arguing about prices. The European Commission now wants them to argue about the future as well, and it has bought a piece of economics to force the conversation. Late in August the Commission released the commissioned study on the dynamic effects of mergers, the last significant evidence input into a rewrite of the merger guidelines that will decide which deals clear the single market for years to come.
Oxera prepared the study, with Professor Otto Toivanen of Aalto University as lead academic researcher and Professors Yassine Lefouili and Leonardo Madio as economic advisers. DG Competition will put the results to an open economic workshop on 11 September at the Solvay Brussels School, and the draft agenda gives away the shape of the fight. One panel carries the title theories of dynamic harm. The next carries theories of dynamic benefits. The Commission has, in effect, staged a debate rather than presented a conclusion.
That caution has a reason. The Commission published draft revised merger guidelines on 30 April, merging the separate horizontal and non-horizontal texts into a single framework for the first time since the mid-2000s. The public consultation closed on 26 June. Officials aim to finish the review in the fourth quarter of this year and adopt the final text around the turn of the year. Whatever the study says will therefore land in a document that competition authorities, judges and deal lawyers read line by line.
The substance turns on a genuinely hard problem. Standard merger analysis measures what happens to price and output after two rivals combine. Dynamic analysis asks what happens to invention, entry and product variety over five or ten years, and the honest answer is that nobody measures those things well. Regulators worry about acquisitions that quietly retire a research pipeline. Companies reply that scale funds research nobody else would finance. Both claims rest on counterfactuals that resist proof.
The speaker list tells its own story. Philippe Aghion, whose work on the inverted-U relationship between competition and innovation shaped the modern literature, delivers the keynote. Nancy Rose of MIT and Chiara Fumagalli of Bocconi sit on the harm panel. Jorge Padilla of Compass Lexecon and Laurent Eymard of BRG, economists who routinely defend transactions before the Commission, take seats on the panels too. Guillaume Loriot, deputy director general for mergers, opens the day and Director General Anthony Whelan closes it.
Business federations will read the study for one thing above all: predictability. Their consultation responses warned that speculative theories of future harm hand case teams a licence to block transactions on narrative rather than evidence, and that Europe cannot demand consolidation in telecoms and defence while treating scale as suspect. The competing view is equally blunt. If enforcement only counts price effects, an acquirer can buy an inconvenient innovator at any price and never trouble a case team, because the harm arrives after the review closes.
The Commission has already run three technical stakeholder workshops on the review, in December, January and June. This one differs because it puts published research on the table rather than opinions, and because the timing leaves barely a quarter before adoption. Watch for whether the final guidelines give dynamic competition its own analytical section with a stated evidential threshold, or whether the concept survives only as language sprinkled through the existing price-centred framework.
The distinction sounds academic. It is not. A threshold written into the guidelines tells a company in advance what evidence about research pipelines it must produce, and tells the General Court what to review. A vague reference does neither, and leaves the argument to be settled case by case in Luxembourg.
